In 2014, a study was published in which other potential IMT actionable targets, including ROS1 and PDGFR beta fusions, were reported for the first time.[21] Genetic analysis was performed by next generation sequencing (NGS) on 33 IMT samples, 11 of which were ALK-negative. Here, ROS1 is linked to inflammatory myofibroblastic tumor.